- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07270575
Resorberbare støttestrukturer med everolimus-avgivelse for behandling av infrapopliteal arteriesykdom hos pasienter med kronisk livstruende ishemi (RESCUE)
Resorberbare støttestrukturer med everolimus-utløsning for behandling av infrapopliteal arteriesykdom hos pasienter med kronisk livstruende ishemi i ekstremitetene
RESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings. The study focuses on people who have heavily calcified arteries in the infrapopliteal areas of the leg.
These drug-eluting resorbable scaffolds release a medication that helps prevent the inner wall of the blood vessel from thickening after injury or surgery. This can reduce the chance of the artery becoming blocked again (a problem called restenosis), while also giving temporary structural support to the vessel. Over time, the scaffold naturally dissolves in the body, which may lower the long-term risks associated with permanent metal stents.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Claire Poulet, PhD
- Telefonnummer: +41 79 385 16 78
- E-post: oracue@cirse.org
Studer Kontakt Backup
- Navn: Dhwani S. Korde, PhD
- Telefonnummer: +4367762942469
- E-post: oracue@cirse.org
Studiesteder
-
-
-
Hull, Storbritannia, HU3 2JZ
- Rekruttering
- Hull University Teaching Hospitals NHS Trust
-
Hovedetterforsker:
- Raghu Lakshminarayan, Dr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Adult CLTI patients treated with the Esprit BTK everolimus-eluting resorbable scaffold following adequate vessel preparation for infrapopliteal artery disease.
Beskrivelse
Inclusion Criteria:
- Rutherford classification category ≥4;
- Treatment of infrapopliteal lesions with the Esprit BTK everolimus eluting resorbable scaffold system following adequate vessel preparation;
- Calcification of target lesions must be visible on fluoroscopy or CT-angiography;
- Patients competent and willing to provide informed consent.
Exclusion Criteria:
- Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);
- Inadequate inflow (>30% stenosis) following optimization;
- Insufficient direct outflow (less than 1 run-off vessel);
- Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;
- Patients planned to receive an above ankle amputation of the target limb;
- Patients enrolled in ORACLE (ClinicalTrials.gov ID NCT07270562).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Adult CLTI patients with infrapopliteal calcified lesions
Adult CLTI patients planned to receive the Esprit BTK™ resorbable scaffold following pre-dilatation with angioplasty balloon. |
The Esprit BTK™ is a bioresorbable vascular scaffold designed for arteries below the knee. It provides temporary support to keep the vessel open while releasing everolimus-an antiproliferative drug that helps prevent excessive tissue growth and reduces the risk of restenosis. As the scaffold delivers the medication, it gradually dissolves, potentially lowering long-term risks associated with permanent stents.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of lesions free from Clinically-Driven Target Lesion Revascularization (CD-TLR)
Tidsramme: 12 months
|
Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
CD-TLR-free survival per target lesion
Tidsramme: Until the end of the follow-up period of 3 years
|
Defined as the time between first index procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
Until the end of the follow-up period of 3 years
|
|
Clinical response using Rutherford classification categories
Tidsramme: 12, 24, and 36 months
|
The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss. |
12, 24, and 36 months
|
|
Wound status
Tidsramme: 12, 24, and 36 months
|
Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening). |
12, 24, and 36 months
|
|
Freedom from major amputation of the target limb
Tidsramme: 12 and 24 months
|
Defined as absence of any amputation of the target limb (above ankle). |
12 and 24 months
|
|
Amputation-free survival
Tidsramme: Until the end of the follow-up period of 3 years
|
Defined as time between first index procedure and amputation of the target limb, minor (digital, metatarsal), major below the knee or major above the knee (excluding any amputation planned before the index procedure). |
Until the end of the follow-up period of 3 years
|
|
Overall survival
Tidsramme: Until the end of the follow-up period of 3 years
|
Defined as the time between the first index procedure and death of any cause. |
Until the end of the follow-up period of 3 years
|
|
Patient-reported health-related quality-of-life
Tidsramme: Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment
|
Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD. |
Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment
|
|
Frequency and severity of procedural complications and other adverse events
Tidsramme: Within 30 days after the index procedure
|
Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe. |
Within 30 days after the index procedure
|
|
Frequency of major adverse limb events (MALE) and peri-operative death (POD).
Tidsramme: 6 months for MALE; Within 30 days after the index procedure for POD
|
MALE include above-ankle amputation in the index limb, major re-intervention on the index limb at 6 months and POD includes perioperative (30-day) mortality. |
6 months for MALE; Within 30 days after the index procedure for POD
|
|
Clinical response using ankle-brachial index (ABI)
Tidsramme: 12, 24, and 36 months
|
The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease. |
12, 24, and 36 months
|
|
Clinical response using toe pressure
Tidsramme: 12, 24, and 36 months
|
The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion. |
12, 24, and 36 months
|
|
Clinical response using WIfi (wound, ischemia and foot infection) score
Tidsramme: 12, 24, and 36 months
|
The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization. |
12, 24, and 36 months
|
|
Restoration of normal lumen per target lesion
Tidsramme: Immediately upon procedure completion
|
Defined as residual stenosis ≤30%, immediately after completion of full planned procedure. |
Immediately upon procedure completion
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Gerd Grözinger, Prof. Dr. med., SLK Kliniken Heilbronn GmbH
- Studiestol: Marianne Brodmann, Univ.-Prof. Dr. med., Medizinische Universität Graz
- Studiestol: Raghu Lakshminarayan, Dr, Hull University Teaching Hospital
- Studiestol: Stefan Müller-Hülsbeck, Prof. Dr. med., DIAKO Krankenhaus gGmBH
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- Perifer arteriesykdom
- CLTI
- Infrapopliteale arterier
- Kritisk ekstremitets-truende iskemi
- Infrapopliteal arteriesykdom
- Esprit BTK Everolimus-frigjørende resorberbar stent
- Legemiddelavgivende resorberbart stent
- Resorberbart vaskulært støttestruktur
- Real-world evidence-studie
- Pasienter med infrapopliteal sykdom
- Kalsifiserte perifere arterielle lesjoner
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- RESCUE
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .